Dabigatran Following Transient Ischemic Attack & Minor Stroke

Status Completed

Clinical Trial Summary

Rationale: To date, anticoagulant therapy in acute stroke has also been limited by excess hemorrhagic events. The oral anticoagulant dabigatran is a novel agent, which has been shown to be associated with much lower intracranial hemorrhage rates. It has been suggested that this agent may provide the superior benefits of anticoagulation in acute stroke, without the concomitant increase in hemorrhage risk associated with heparin/LMWH or warfarin.

Study Design: DATAS II is a randomized, open label blinded endpoint trial. Participants (n=300) with TIA or ischemic stroke (NIHSS score <9) will be enrolled within 48 hours of symptom onset from approximately four (4) health care centres across Canada. All participants will have an MRI with DWI lesion volume < 25 ml. Participants will be randomized 1:1 to treatment with dabigatran for 30 days or ASA 81 mg daily (current standard of care). All stroke patients will initially be screened with a non-contrast CT scan of the brain. The first MRI will be performed within 48 hours of symptom onset. Imaging studies will be repeated at day 30. All patients will be assessed clinically at Day 30 and Day 90.

Study Aims:

1. Establish the safety of early anticoagulation with the novel oral anticoagulant dabigatran in acute cerebrovascular syndrome patients.

2. Identify the rate of both symptomatic and asymptomatic hemorrhagic transformation (HT) associated with these treatments.

3. Identify predictors of HT associated with acute dabigatran treatment.

Hypothesis: The Investigators hypothesize that symptomatic HT rates in dabigatran and ASA treated patients will not be significantly different.

Study outcomes: The primary outcome is the rate of symptomatic hemorrhagic transformation (HT), defined as a parenchymal hematoma, which is >30% of the infarcted area on DWI, with substantial space- occupying effect, associated with clinical worsening (≥4 point increase in National Institutes of Health Stroke Scale (NIHSS) score) within 5 weeks of treatment initiation. The major secondary outcome the rate of asymtomatic HT see on day 30 MRI sequence.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02295826
Study type	Interventional
Source	University of Alberta
Contact
Status	Completed
Phase	Phase 2
Start date	January 2015
Completion date	December 18, 2018

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT00859885` - International PFO Consortium	N/A
Not yet recruiting	`NCT03605355` - Feasibility Study on the Medical and Economic Consequences of Outpatient Management of TIAs and Minor Strokes
Completed	`NCT03281590` - Stroke and Cerebrovascular Diseases Registry
Completed	`NCT02905383` - The Effect of Exercise on Physical Function and Health in Older People After Discharge From Hospital	N/A
Completed	`NCT04078737` - Clopidogrel With Aspirin in High-risk Patients With Acute Non-disabling Cerebrovascular Events II	Phase 3
Completed	`NCT02141932` - Pocket-size Cardiovascular Ultrasound in Stroke	N/A
Recruiting	`NCT01954329` - Markers in the Diagnosis of TIA	N/A
Completed	`NCT02011256` - Early Detection Of Atrial Fibrillation In Patients With Transient Ischemic Attack	N/A
Completed	`NCT01918891` - Center for Stroke Disparities Solution - Community Transitions Intervention	N/A
Recruiting	`NCT01526824` - Lovaza's Effect on Clopidogrel in a Neuro Population	Phase 0
Completed	`NCT01020851` - The PREVENTS Trial: The Preventing Recurrent Events in Veterans Navigating Transient Ischemic Attack (TIA) or Stroke Trial	N/A
Completed	`NCT00597974` - Neurological Outcome With Carotid Artery Stenting	N/A
Completed	`NCT00211731` - Preventing Recurrent Stroke in Minority Populations	N/A
Active, not recruiting	`NCT03635749` - Intensive Medical Therapy for High-risk Intracranial or Extracranial Atherosclerosis	Phase 3
Completed	`NCT03153020` - Determinants of Adherence to Post-stroke/Transient Ischemic Attack Secondary Prevention Treatment: Cohort Study in the Rhône
Recruiting	`NCT04075500` - Optimal Detection of Atrial Fibrillation in TIA	N/A
Recruiting	`NCT06091319` - Florbetaben for Imaging of Vascular Amyloid
Completed	`NCT04604015` - RoBotic TCD Ultrasound BubbLe Study Compared to Transthoracic Echocardiography for Detection of Right to Left Shunt	N/A
Completed	`NCT00885456` - Program of Rehabilitative Exercise and Education to Avert Vascular Events After Non-disabling Stroke or Transient Ischemic Attack: A Multi-site RCT	Phase 2
Completed	`NCT05620966` - EEG to Diagnose TIA and Stroke

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Dabigatran Following Transient Ischemic Attack and Minor Stroke — DATAS II

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms